56935-74-1

Basic information

• Product Name: N-Hydroxy-4-Methanesulfonylbenzene-1-carboxiMidaMide
• Synonyms: N-Hydroxy-4-Methanesulfonylbenzene-1-carboxiMidaMide;Benzenecarboximidamide, N-hydroxy-4-(methylsulfonyl)-;N'-hydroxy-4-(methylsulfonyl)benzamidine
• CAS NO: 56935-74-1
• Molecular Formula: C₈H₁₀N₂O₃S
• Molecular Weight: 214.2416
• Mol File: 56935-74-1.mol
• Article Data: 8

Chemical Properties

• Appearance: /
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• CAS DataBase Reference: N-Hydroxy-4-Methanesulfonylbenzene-1-carboxiMidaMide(CAS DataBase Reference)
• NIST Chemistry Reference: N-Hydroxy-4-Methanesulfonylbenzene-1-carboxiMidaMide(56935-74-1)
• EPA Substance Registry System: N-Hydroxy-4-Methanesulfonylbenzene-1-carboxiMidaMide(56935-74-1)

Safety Data

• Hazardous Substances Data: 56935-74-1(Hazardous Substances Data)

Upstream product

• 22821-76-7 4-(methylsulfonyl)benzonitrile 
• 5470-49-5 4-methanesulfonylphenylamine 
• 21382-98-9 p-cyanophenyl methyl sulfide 
• 104-96-1 4-methylsulfanylaniline 

Downstream Products

• 918967-72-3 3-(4-methanesulfonylphenyl)-[1,2,4]oxadiazol-5-ol 
• 1103310-87-7 4-[3-(4-methanesulfonyl-phenyl)-[1,2,4]oxadiazol-5-ylmethyl]-piperidine-1-carboxylic acid tert-butyl ester 

Relevant articles and documents

Novel benzimidazole-oxadiazole hybrid molecules as promising antimicrobial agents

In the present study, we describe the design and expeditious synthesis of novel 2-aryl-5-(3-aryl-[1,2,4]-oxadiazol-5-yl)-1-methyl-1H-benzo[d]imidazole hybrid molecules as promising antimicrobial agents. The core moiety 2-aryl-ethyl-1H-benzo[d]imidazole-5-

HETEROAROMATIC COMPOUNDS FOR USE AS HIF INHIBITORS

The present application relates to novel substituted aryl compounds, processes for their preparation, their use for treatment and/or prevention of diseases and their use for the preparation of medicaments for treatment and/or prevention of diseases, in particular for treatment and/or prevention of hyperproliferative and angiogenic diseases and those diseases which arise from metabolic adaptation to hypoxic states. Such treatments can be carried out as monotherapy or also in combination with other medicaments or further therapeutic measures.

NOVEL HETEROCYCLIC METHYLENE PIPERIDINE DERIVATIVES AND THEIR USE

The present invention is directed to compounds of formula (I) compositions comprising them and their use.